BioWorld Asia

May 5, 2010

Oxford Immunotec Raises $26M to Boost T-Cell Tests Worldwide

LONDON - Oxford Immunotec Ltd. raised $26 million in a fourth-round funding, which it said will enable it to increase sales of its T-cell diagnostic for tuberculosis and take the company through to profitability. (BioWorld International) Read More

Asian Pacific Biotechs Branch Out from Health to White Tech

Study Pinpoints Viral RNA Targets for Future Drugs

Huntington's Drug Snagged on Statistics; Another Trial Needed?

BIO in Chicago: BioWorld Waxes Nostalgic, Biotech Perseveres

Affimed Plans to Take Antibodies into Clinic with $26M Series C

Protox's $75M Kissei Deal May Set Stage for Larger Alliances

Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...